Technical Analysis for KMDA - Kamada Ltd.

Grade Last Price % Change Price Change
grade A 5.33 0.76% 0.04
KMDA closed up 0.76 percent on Friday, January 18, 2019, on 37 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Feb 6

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Flat
See historical KMDA trend table...

Date Alert Name Type % Chg
Jan 18 Crossed Above 200 DMA Bullish 0.00%
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Fell Below 200 DMA Bearish 0.76%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.76%
Jan 17 Narrow Range Bar Range Contraction 0.76%
Jan 17 Overbought Stochastic Strength 0.76%
Jan 16 200 DMA Support Bullish 0.00%
Jan 16 180 Bullish Setup Bullish Swing Setup 0.00%
Jan 16 Narrow Range Bar Range Contraction 0.00%

Older signals for KMDA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Kamada Ltd., a biopharmaceutical company, develops, produces, and markets therapeutics based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases; Heparin Lock Flush to maintain potency of intravenous injection device; Kamacaine 0.5%, a spinal and epidural anesthesia; and Albumin for therapeutic plasma exchange and hypovolemic shock. In addition, the company offers Factor IX for treatment of bleeding episodes and to maintain plasma factor IX levels; Factor VIII, VWF for the treatment of bleeding episodes to maintain plasma factor VIII level, vonwillebrand disease; and Human Transferrin for in vitro and diagnostic use. Its development stage products include Aerosolized AAT, which is in Phases II-III clinical trials for alpha-1 antitrypsin deficiency, and under Phase II clinical trial for bronchiectasis, as well as completed Phase II clinical trial for cystic fibrosis; Human Transferrin for pharmaceutical use; and snake antiserum for snake bites. The company has a collaboration partnership with PARI for the development of an aerosolized AAT treatment. Kamada Ltd. sells its products through distributors worldwide, as well as is involved in marketing of imported complementing products in Israel. The company was founded in 1990 and is headquartered in Ness Ziona, Israel.
Is KMDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.45
52 Week Low 4.35
Average Volume 9,279
200-Day Moving Average 5.3252
50-Day Moving Average 5.1499
20-Day Moving Average 5.1295
10-Day Moving Average 5.305
Average True Range 0.1014
ADX 22.29
+DI 30.4237
-DI 18.8042
Chandelier Exit (Long, 3 ATRs ) 5.0958
Chandelier Exit (Short, 3 ATRs ) 5.0042
Upper Bollinger Band 5.5336
Lower Bollinger Band 4.7254
Percent B (%b) 0.75
BandWidth 15.755922
MACD Line 0.0727
MACD Signal Line 0.0421
MACD Histogram 0.0306
Fundamentals Value
Market Cap 199.34 Million
Num Shares 37.4 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -106.60
Price-to-Sales 2.15
Price-to-Book 2.76
PEG Ratio 9.35
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.38
Resistance 3 (R3) 5.38 5.37 5.37
Resistance 2 (R2) 5.37 5.36 5.37 5.36
Resistance 1 (R1) 5.35 5.35 5.35 5.35 5.36
Pivot Point 5.34 5.34 5.34 5.34 5.34
Support 1 (S1) 5.32 5.33 5.32 5.32 5.30
Support 2 (S2) 5.31 5.32 5.31 5.30
Support 3 (S3) 5.29 5.31 5.29
Support 4 (S4) 5.29